Smith & Nephew Interventional Pain Assets
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Smith & Nephew Interventional Pain Assets - overview
Location
London, England, UK
Primary Industry
Healthcare Specialists
About
Smith & Nephew Interventional Pain Assets is a medical technology company specializing in advanced solutions for managing pain, focusing on the repair and regeneration of soft and hard tissue through innovative surgical techniques. Smith & Nephew Interventional Pain Assets operates within the medical technology sector, specifically addressing pain management through advanced products and services. Founded by Sydney Stafford, the company is headquartered in London, UK, and part of a broader portfolio managed by Smith & Nephew PLC. The company has undergone significant strategic pivots, including the acquisition of its Interventional Spine Pain Management business by NeuroTherm, Inc.
in April 2010, which reflects a shift in its operational focus. The current leadership includes CEOs Deborah Madonini, Deepak Nath, Michael Störk, Roland Diggelmann, and Stefano Marchese. Smith & Nephew is a portfolio medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue. Their core product offerings include advanced technologies and solutions across various sectors, including Orthopaedics, Sports Medicine, Ear, Nose, and Throat (ENT), and Advanced Wound Management.
Key products within these categories are innovative hip and knee implants, robotics-assisted surgical tools, and advanced wound care solutions such as the RENASYS Negative Pressure Wound Therapy System and ALLEVYN LIFE Foam Dressing. Designed to address complex clinical needs, these products serve a diverse client base that includes healthcare professionals, hospitals, ambulatory surgery centers, and rehabilitation facilities. Smith & Nephew’s products are marketed in numerous geographical regions, including North America, Europe, Asia Pacific, and Latin America, catering to both acute and chronic healthcare challenges faced by patients globally. In the most recent financial year of 2023, Smith & Nephew generated revenue of USD 38.
65 mn, with an EBITDA of USD 3. 09 mn. The company's revenue model is structured around the sale of medical devices and solutions, primarily through business-to-business transactions with healthcare institutions. Smith & Nephew is currently focusing on expanding its product portfolio with upcoming innovative solutions aimed at enhancing pain management techniques.
The company plans to enter new markets, specifically targeting areas in Asia Pacific and Latin America by the end of 2024. Recent funding from various transactions will be utilized to support these initiatives, ensuring the development and launch of new products that address evolving medical needs. The company’s most recent notable deal in April 2010, involving the acquisition of its Interventional Spine Pain Management business, has set a foundation for its strategic growth.
Current Investors
NeuroTherm, Ltd.
Primary Industry
Healthcare Specialists
Sub Industries
Chiropractic, Orthopedic & Physical Therapy
Website
www.smith-nephew.com
Verticals
Social Media
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Smith & Nephew Interventional Pain Assets - timeline of key events
Smith & Nephew Interventional Pain Assets - financials
| Fiscal Year Ended | Apr 24, 2010 | Apr 30, 2011 | Apr 28, 2012 | Apr 27, 2013 | Apr 26, 2014 | Apr 25, 2015 | Apr 30, 2016 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 34,059,000 | 61,276,000 | 68,434,000 | 63,832,000 | 58,070,000 | 48,931,000 | 47,329,000 | 30,049,000 | 45,320,000 | 39,842,000 | 42,105,000 | 35,175,000 | 33,251,000 | - | - | - |
| % Revenue Growth (YoY) | - | 79.9% | 11.7% | (6.7%) | (9.0%) | (15.7%) | (3.3%) | - | - | (12.1%) | 5.7% | (16.5%) | (5.5%) | - | - | - |
| EBITDA (USD) | (5,183,000) | 4,736,000 | 6,908,000 | 3,205,000 | 2,767,000 | 3,568,000 | 912,000 | 3,050,000 | 4,747,000 | 774,000 | 1,369,000 | 1,223,000 | 145,000 | - | - | - |
| Operating Income (USD) | (6,303,000) | 2,719,000 | 4,551,000 | 282,000 | 580,000 | 1,437,000 | (1,249,000) | 1,674,000 | 2,755,000 | (1,209,000) | (776,000) | (890,000) | (1,949,000) | - | - | - |
| Operating Margin | (18.5%) | 4.4% | 6.7% | 0.4% | 1.0% | 2.9% | (2.6%) | 5.6% | 6.1% | (3.0%) | (1.8%) | (2.5%) | (5.9%) | - | - | - |
| % EBITDA Margin | (15.2%) | 7.7% | 10.1% | 5.0% | 4.8% | 7.3% | 1.9% | 10.2% | 10.5% | 1.9% | 3.3% | 3.5% | 0.4% | - | - | - |
| NET Income (USD) | (8,024,000) | 7,871,000 | 3,019,000 | (1,842,000) | (1,023,000) | 495,000 | (1,484,000) | 1,447,000 | 2,341,000 | (1,601,000) | (885,000) | (1,087,000) | (1,843,000) | - | - | - |
| % Net Margin | (23.6%) | 12.8% | 4.4% | (2.9%) | (1.8%) | 1.0% | (3.1%) | 4.8% | 5.2% | (4.0%) | (2.1%) | (3.1%) | (5.5%) | - | - | - |
Smith & Nephew Interventional Pain Assets - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Smith & Nephew Interventional Pain Assets | - |
Displaying 1 - 1 of 1
Smith & Nephew Interventional Pain Assets - employee data
Smith & Nephew Interventional Pain Assets - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Styrelseordförande | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.